Novavax gets green light from FDA, awaits CDC recommendation for booster COVID doses.
The Serum Institute of India has received a recommendation from WHO for malaria doses using a Novavax adjuvant.
Moderna’s combined Covid and influenza vaccine was as effective as separate shots in an early stage trial, giving the US biotech company hope that the more convenient way of protecting against the diseases could be approved by 2025. Interim data measuring antibody levels from the phase-1/2 trial showed the combined jab elicited a similar or greater immune response to flu viruses as currently approved flu vaccines, including Sanofi’s high-dose shots designed for the elderly. The jab also elicited a similar immune response to Sars-Cov-2 as Moderna’s Covid-19 booster, known as Spikevax.